|1.||Blagg, Brian S J: 13 articles (09/2015 - 09/2005)|
|2.||Donnelly, Alison C: 4 articles (12/2011 - 11/2008)|
|3.||Dobrowsky, Rick T: 3 articles (09/2015 - 06/2012)|
|4.||Vielhauer, George A: 3 articles (02/2015 - 01/2010)|
|5.||Holzbeierlein, Jeffrey M: 3 articles (02/2015 - 01/2010)|
|6.||Zhao, Huiping: 3 articles (08/2014 - 06/2011)|
|7.||Holzbeierlein, Jeffrey: 3 articles (06/2011 - 03/2008)|
|8.||Vielhauer, George: 3 articles (06/2011 - 03/2008)|
|9.||Le Bras, Gaëlle: 3 articles (02/2009 - 11/2007)|
|10.||Brion, Jean-Daniel: 3 articles (02/2009 - 11/2007)|
02/01/2012 - "In particular, novobiocin, with the best selectivity index (SI = 31.62) among the inhibitors tested in this study, is effective in inhibiting KSHV DNA replication and virion production but shows little adverse effect on cell proliferation and cycle progression in its therapeutic concentration, suggesting its potential to become an effective and safe drug for the treatment of human diseases associated with KSHV infection."
10/01/1979 - "A significant reduction (P < 0.05) in the overall rate of new udder infections acquired during the dry period was observed in cows treated with >/= 200 mg novobiocin at drying off. "
06/01/1982 - "The younger females in the study tended to have infection due to novobiocin resistant Staphylococcus in contrast to males and older females."
06/01/1958 - "The use of novobiocin for treament of infections of odontogenic origin; a preliminary clinical study."
01/01/1956 - "Novobiocin; a limited clinical and bacteriologic study of its use in infants and children with Staphylococcus aureus infections."
06/01/2010 - "Comparative efficacy of novobiocin and amoxicillin in experimental sepsis caused by beta-lactam-susceptible and highly resistant pneumococci."
06/01/2010 - "In sepsis, novobiocin and amoxicillin were evaluated at 25, 50, 100 and 200 mg/kg given at 1, 5, 24 and 48 h post bacterial challenge. "
06/01/2010 - "Novobiocin, an old antibiotic, was tested in vitro and in a murine sepsis model against one amoxicillin-susceptible and three amoxicillin-resistant strains [minimum inhibitory concentrations (MICs) 8-64 mg/L]. "
01/01/1957 - "Clinical observations on the use of novobiocin in penicillin-resistant staphylococcal septicemia."
01/01/1984 - "The efficacy of papain, a proteolytic enzyme made in the USSR, was studied alone and in combination with antibiotics, such as benzylpenicillin, streptomycin, chloramphenicol, tetracycline, erythromycin and novobiocin in treatment of mice with septicemia caused by antibiotic-resistant staphylococci. "
03/01/1999 - "Among the mastitis strains tested, 6789 and 6806 were more susceptible to killing by novobiocin than was strain 6800. "
01/01/1995 - "Novobiocin is used for the treatment of mastitis in dairy cattle. "
12/01/1959 - "Novobiocin and predinsolone in puerperal mastitis."
01/01/1957 - "Novobiocin therapy in puerperal mastitis."
06/01/2002 - "High prevalence of infections by novobiocin-sensitive staphylococci together with high SCC related to such infections show a relevant role of these organisms in ewe mastitis. "
|4.||Melanoma (Melanoma, Malignant)
01/01/1994 - "These data show that novobiocin increases the sensitivity of both parental and MDR melanoma cells to microtubule-disrupting cytotoxic drugs."
02/01/1992 - "Our results support the contention further that novobiocin and other differentiating agents might be of potential value in melanoma therapy."
10/01/1982 - "The effect of novobiocin on the formation of DNA replication intermediates in human melanoma cells was investigated. "
10/01/1982 - "Formation of a new DNA replication intermediate in novobiocin-treated human melanoma cells."
12/22/2011 - "We investigated a novobiocin-derived Hsp90 C-terminal inhibitor, KU135, for anti-proliferative effects in melanoma cells. "
|5.||Interferon-alpha (Interferon Alfa)
|7.||Type II DNA Topoisomerases (Topoisomerase II)
|9.||DNA (Deoxyribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)
|4.||Hematopoietic Stem Cell Mobilization